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Abstract 53 
Rationale 54 
We evaluated whether treatment outcomes for patients with multidrug-resistant and 55 
extensively drug-resistant tuberculosis can be substantially improved, when sufficient 56 
resources for personalizing medical care are available. 57 
Objectives 58 
To describe the characteristics and outcomes of patients with pulmonary multidrug-59 
resistant tuberculosis from the Otto Wagner Hospital in Vienna, Austria. 60 
Methods 61 
Retrospective single-centre study at the Otto-Wagner-Hospital, Vienna, Austria. The 62 
records of patients with multidrug-resistant tuberculosis were reviewed for 63 
epidemiological, clinical, laboratory, treatment and outcome data. 64 
Results 65 
Ninety patients with pulmonary multidrug-resistant tuberculosis were identified. 66 
Median age was 30 years (interquartile range 26-37). All patients were of non-67 
Austrian origin and 70 (78%) came from the former Soviet Union States.  Thirty-nine 68 
(43%) patients had multidrug-resistant tuberculosis, 28 (31%) had additional bacillary 69 
resistance to at least one second-line injectable drug, 9 (10%) to a fluoroquinolone, 70 
14 (16%) patients had extensively drug-resistant tuberculosis. In 97.8% (n=88) of 71 
patients different drug combinations were used for treatment. Sixty-five (72.2%) 72 
patients had a successful treatment outcome, 8 (8.9%) defaulted, 3 (3.3%) died, 8 73 
(8.9%) continued treatment in another country and their outcome was unknown, and 74 
6 (6.7%) were still on therapy. None of the patients experienced treatment failure. 75 
Treatment outcome for extensively drug-resistant tuberculosis was similar to that of 76 
multidrug-resistant tuberculosis.  77 
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Conclusions 78 
High rates of treatment success can be achieved in patients with multidrug-resistant 79 
and extensively drug-resistant tuberculosis when individualized tailored treatment 80 
regimen can be provided. 81 
 82 
Number of words in Abstract: 228 83 
 84 
Key words: drug resistance, MDR-TB, outcome, treatment, tuberculosis 85 
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Introduction 86 
Despite Global efforts, tuberculosis (TB) remains a leading cause of morbidity and 87 
mortality representing the tenth most common cause of death worldwide (1). 88 
Although the incidence of TB has registered a descending trend in recent years, the 89 
emergence and increase in multidrug- resistant (MDR) TB incidence is a cause of 90 
great concern. According to the World Health Organization (WHO), an estimated 91 
480,000 cases of MDR-TB have occurred in 2013 resulting in 210,000 deaths (2). 92 
MDR-TB is defined as bacillary resistance to isoniazid and rifampicin, while 93 
extensively drug-resistant (XDR)-TB is defined by additional resistance to at least 94 
one second-line injectable drug (amikacin, kanamycin, capreomycin) and at least 95 
one fluoroquinolone (3). The WHO recommends that patients with MDR-TB receive 96 
prolonged antimicrobial treatment of at least 20 months (4), including a minimum of 4 97 
second-line drugs that are likely to be effective in the therapy plus pyrazinamide. 98 
MDR-TB treatment is frequently associated with adverse drug events (5), with high 99 
costs (6), and high rates of loss to follow-up and failure (7-11). Additionally, owing to 100 
limited possibilities to test for drug-resistance and to optimise regimens in many 101 
settings where the global burden of MDR-TB is highest, treatment for MDR-TB is 102 
often standardized irrespective of the severity of disease and the resistance pattern 103 
of the associated strain. 104 
Poor treatment outcomes were reported in a meta-analysis of over 6700 patients, 105 
where MDR-TB treatment success ranged from 64% in patients with MDR-TB and 106 
no additional resistance to injectable drugs or fluoroquinolones to 40% in patients 107 
with XDR-TB (8). Additionally, according to data from the European Centre for 108 
Disease Prevention and Control (ECDC) analysing treatment outcomes, treatment 109 
success was registered in only 46% of MDR-TB and only 23.2% of XDR-TB cases 110 
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(10). Furthermore, access to MDR-TB treatment is often difficult with only a third of 111 
the estimated cases being enrolled on treatment in 2013 (2). 112 
While the European Region of the WHO has the highest proportion of all patients 113 
with MDR-TB identified world-wide, the vast majority of these patients live in eastern 114 
part of the European Region, especially in countries from the former Soviet Union. 115 
Compared to the European Union/ European Economic Area countries, where a total 116 
of only 1255 patients with laboratory-confirmed MDR-TB were identified in 2013, 117 
there were 33,679 patients with MDR-TB identified in Eastern Europe during the 118 
same time period (10). Furthermore, an estimated 100,000 MDR-TB cases occurred 119 
in India in China (2). 120 
Poor treatment outcomes that have been reported for MDR-TB may not be 121 
applicable when resources for diagnosis and treatment are readily available and 122 
MDR-TB management can be optimized. Austria has a low incidence of TB, where 123 
only 16 patients with M/XDR-TB were registered in 2013 (12), more than half (57%) 124 
of the patients diagnosed with MDR-TB from Austria are treated at the Otto-Wagner 125 
Hospital in Vienna. This hospital has a dedicated unit for the treatment of patients 126 
with M/XDR-TB, where highly specialized care can be provided under optimal 127 
circumstances. In addition to continuous and unrestricted drug-availability as well as 128 
rigorous monitoring during the course of therapy (clinical, laboratory, microbiological 129 
and radiological), the management of all patients includes regular physiotherapy and 130 
psychological counselling sessions supporting treatment adherence and coping with 131 
the adverse events of therapy. Considering the large number of patients originating 132 
from outside Austria, interpreters are present when required, to assist patients with 133 
communication issues. Furthermore social workers form the department of public 134 
health as well as an on-site fully-dedicated social worker, provide assistance with the 135 
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administrative and insurance-related issues and organize further care after discharge 136 
from hospital. 137 
We evaluated treatment outcomes for patients with M/XDR-TB under personalized 138 
medical care. 139 
Some of the results of this study have been previously reported in the form of an 140 
abstract (13). 141 
 142 
 143 
Methods 144 
Patient population 145 
Patients with microbiologically-confirmed pulmonary MDR-TB and positive cultures 146 
for M. tuberculosis from respiratory samples, admitted at the Otto Wagner Hospital, 147 
Vienna for treatment between January 2003 and December 2012 were included in 148 
the study. Otto Wagner Hospital is a referral center with extensive expertise in the 149 
treatment of patients with TB from Austria. 150 
Data collection 151 
Patients were identified using the department patient register which included all 152 
patients with M/XDR-TB hospitalized at the site. Entries were cross-referenced with 153 
the microbiological registries to identify M. tuberculosis strains with rifampicin and 154 
isoniazid resistance. Patient records were reviewed for epidemiological, clinical, 155 
laboratory, treatment and outcome data and information was recorded in an 156 
anonymized database which was further analysed.  157 
 158 
Drug susceptibility testing 159 
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Drug susceptibility testing was performed in a specialized laboratory at the Institute 160 
for Medical Microbiology and Hygiene, Austrian Agency of Health and Food Safety 161 
and confirmed at the National Reference Center for Mycobacteriology, Borstel, 162 
Germany, one of the WHO supranational reference laboratory for tuberculosis. All 163 
patients included in the study had a positive Mycobacterium tuberculosis culture 164 
available for drug susceptibility testing.  165 
Susceptibility testing was performed for the following drugs: isoniazid, rifampicin, 166 
rifabutin, ethambutol, pyrazinamide, streptomycin, amikacin, capreomycin, 167 
fluoroquinolones, prothionamide, cycloserine, para-aminosalicylic acid (PAS), and 168 
linezolid. 169 
 170 
Treatment and outcome 171 
Patients were considered to receive an appropriate MDR-TB treatment-regimen 172 
once they received at least 4 drugs in combination therapy that were thought to be 173 
effective according to the results of drug susceptibility testing, including a second-174 
line injectable drug for the intensive phase of treatment (14). TB treatment was 175 
directly observed during the whole course of therapy. To ascertain the 176 
microbiological response to treatment, sputum cultures were collected on a monthly 177 
basis during hospitalization and every 1-2 months onwards until the end of therapy. 178 
Outcome was ascertained using the revised WHO definitions (3). Patients were 179 
considered to have a favourable outcome if they were either cured or had completed 180 
the treatment or an unfavourable outcome in the case of default, treatment failure or 181 
death.  182 
 183 
Statistical analysis 184 
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Data processing and analysis were performed using SPSS v17.0 (SPSS Inc., 185 
Chicago, IL, USA). Mann-Whitney U test was used to test for differences between 186 
continuous variables and chi-square test or Fisher’s exact test were used for 187 
categorical variables. The level of significance was set at α=0.05. Multivariate 188 
analysis using backward stepwise logistic regression was then used to predict 189 
treatment outcome when the p-value from the univariate analysis was <0.20. 190 
 191 
Ethics 192 
The study was approved by the ethics committee of the city of Vienna 193 
(Ethikkommission der Stadt Wien: EK 14-240-VK). 194 
 195 
 196 
Results 197 
Patient characteristics 198 
A total of 94 patients with M/XDR-TB who were admitted during the study period 199 
were identified. Four patients had extrapulmonary M/XDR-TB, and were excluded 200 
from the analysis. Median patient age at diagnosis was 30 years (interquartile range 201 
(IQR) 26-37). Male to female ratio was 1.5:1. All patients were of non-Austrian origin 202 
and came from the Russian Federation (n=55, 61.1%), Georgia (n=11, 12.2%), 203 
Romania (n=11, 12.2%) or other countries (13, 14.4%). Fifty of the patients from the 204 
Russian Federation were from Chechnya. Seventeen patients were intravenous drug 205 
users, and 52 (58%) were active smokers. All patients were tested for HIV infection, 206 
but none were HIV-seropositive. The characteristics of the patients included in the 207 
study are presented in Table 1. 208 
 209 
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Drug susceptibility testing 210 
Thirty-nine (43%) patients had MDR-TB only, 28 (31%) had additional resistance to 211 
at least one second-line injectable drug, 9 (10%) to a fluoroquinolone, while 14 212 
(16%) of patients had XDR-TB. The patients with XDR-TB were originally from 213 
Chechnya (n=9), Romania (n=3), Georgia (n=1) and China (n=1). Resistance to at all 214 
first-line drugs was recorded in 40 (44%) of patients. The results of the drug 215 
susceptibility testing are shown in Figure 1. Of note is that 8 (8.9%) M. tuberculosis 216 
strains were susceptible to rifabutin. 217 
 218 
Management and treatment outcome 219 
Median time from hospital admission to the start of an appropriate M/XDR-TB 220 
treatment was 23.5 days (IQR 0.8-45).  221 
Eighty-eight different drug combinations were used for the treatment of the 90 222 
patients (97.8%) treatment. The drug regimens according to their composition are 223 
represented in Figure 2. The intensive phase contained a median of 5 drugs (IQR 5-224 
6), while in the continuation phase, a median of 3 drugs (IQR 3-4) were used. 225 
Smear conversion occurred after a median 61 days (IQR 22-135) following the 226 
initiation of adequate treatment while culture conversion occurred after a median of 227 
62 days (34-112.8 days).  Only 3 (3.3%) patients did not experience a culture 228 
conversion. Figure 3 shows smear and culture conversion during anti-TB treatment. 229 
Culture conversion occurred in 40 (46%) patients within the first 2 months of effective 230 
M/XDR-TB therapy, and in 72 (82.8%) patients within 6 months. 231 
The median duration of the intensive phase was 123 days (IQR 82-228) and 232 
continuation phase was 494 days (IQR 388-599 days). The overall median duration 233 
of therapy was 21 months (IQR 18-24 months); in patients with a favourable 234 
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outcome, the median duration of therapy was 23 months (IQR 19-24 months) while 235 
in patients who experienced an unfavourable outcome it was 4 months (IQR 3-18 236 
months, p <0.001). One patient defaulted before therapy could be initiated. 237 
The median duration of inpatient stay was 141 days (IQR 96.5-230.3 days) while the 238 
median duration of treatment in the out-patient setting was of 15 months (IQR 12-23 239 
months).. Patients with smear positive tuberculosis had a significantly longer hospital 240 
stay with a median duration of 191 days (IQR 108.5-243) compared to smear 241 
negative patients - median duration 102.5 days (IQR 67.5-134.8, p <0.001). 242 
Additionally, the median length of hospital stay was longer in patients with XDR-TB 243 
in comparison to patients with non-XDR-TB (335 vs. 128 days, p <0.001). 244 
Surgery was performed in 10 (11.1%) of patients. Of the nine patients with a known 245 
outcome, 6/9 (66.7%) had a favourable outcome. For facilitating the administration of 246 
parenteral therapy, 48 (53.3%) of patients received a totally implantable central 247 
venous access system (port-a-cath).  248 
As shown in Table 2, 65 (72.2%) patients had a favourable treatment outcome (56 249 
fulfilled the criteria for cure and 9 completed treatment), 8 (8.9%) defaulted, 3 (3.3%) 250 
died, 8 (8.9%) continued the treatment in their home-country after hospital discharge 251 
and their outcome was therefore unknown, and 6 (6.7%) were still on therapy. One 252 
of the patients who died had concomitant central nervous system TB. If only the 253 
cases with a known outcome are considered, then 85.5% of patients had a 254 
successful outcome. Out of 14 patients with XDR-TB, nine (64%) were cured, one 255 
(7%) died and four (29%) were still on treatment. None of the patients included in the 256 
study experienced treatment failure. Of the seven patients who were treated with 257 
bedaquiline, five were still on treatment when the data were analysed, one was 258 
transferred to another treatment facility and one died. All patients treated with 259 
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bedaquiline, who had a prolonged culture positivity, achieved culture conversion. Of 260 
the 14 patients who had received fusidic acid, 13 had a favourable outcome, while 261 
one died (p=0.68). In the univariate analysis the duration of therapy (p <0.01), 262 
treatment with cycloserine (p <0.01), not receiving treatment with pyrazinamide 263 
(p=0.04) and a negative culture status at six months (p=0.04) were associated with a 264 
favourable treatment outcome. In the multivariate analysis the duration of therapy 265 
(OR 0.66, 95%CI 0.51-0.86; p=0.002) and culture status at 6 months (OR 0.04, 266 
95%CI 0.02-0.70; p=0.03) were associated with a favourable outcome. 267 
 268 
Adverse events 269 
Gastrointestinal adverse events occurred in 74 (82.2%) patients, polyneuropathy in 270 
48 (53.3%), ototoxicity in 31 (34.4%), psychiatric adverse effects in 44 (48.9%), and 271 
liver enzymes were elevated during therapy in 44 (48.9%) of patients. Treatment with 272 
linezolid was more frequently associated with polyneuropathy (62.3% versus 34.5%, 273 
p=0.023), while ototoxicity was associated with amikacin therapy (52.2% versus 274 
28.4%, p=0.046). Ototoxicity was present in 25% of patients who had received 275 
capreomycin versus 42% of patients without capreomycin treatment, p=0.92.  276 
 277 
 278 
Discussion 279 
While treatment outcome for patients with M/XDR-TB in Europe are frequently 280 
reported to be poor (15), we are able to show that treatment outcomes for pulmonary 281 
M/XDR-TB can be substantially improved in a setting where patient management is 282 
individualized. By using tailored drug regimen, treatment success rates close to the 283 
target proposed by the WHO (13)  can be achieved. In this study from a single 284 
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referral centre in Austria treatment success rates were over 72%, (and over 85% in 285 
patients with a definite outcome) which contrasts with the ECDC data which reports 286 
a successful treatment outcome in only 46% of patients from Europe (10). One 287 
explanation for this large difference might be the incomplete reporting of treatment 288 
outcomes to the ECDC and a larger proportion of lost to follow-up due to migration, 289 
as well as an offsetting contribution by countries with a large number of MDR-TB 290 
patients and low treatment success rates such as Romania and Lithuania (10). 291 
Furthermore, individualized therapy is also likely to have played an important 292 
contribution to achieving high rates of treatment success, considering that in this 293 
study 88 different drug-combinations were used.  294 
With the advent of two new drugs for the treatment of MDR-TB and XDR-TB, 295 
treatment outcomes may improve substantially. As 6 of the 7 patients receiving a 296 
bedaquiline based treatment regimen experienced sustained culture conversion it is 297 
hoped that treatment outcomes may improve in general in the European region, 298 
when these drugs will become universally available.  Recently it has been reported, 299 
that 28 of 29 (97%) patients with culture-positive pulmonary M/XDR-TB who were 300 
treated with a bedaquiline containing regimen, experienced culture conversion at 6 301 
months of treatment (16). Furthermore, the 6 months culture status is a very good 302 
approximation for achieving a successful treatment outcome in patients treated for 303 
MDR-TB (17). 304 
While analyses of large patient cohorts describe unfavourable outcomes in more 305 
than half of patients with MDR-TB, studies from individual countries or specialized 306 
centres report significantly higher rates of treatment success. For example, studies 307 
on selected patient cohorts from other European countries, describe treatment 308 
success rates of 59% in Germany (18), 68% in Belgium (19), 71% in the United 309 
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Kingdom (20), 76% in Switzerland (21), and 79% in the Netherlands (22). 310 
Interestingly, the overall and MDR-TB treatment success rates in Austria were lower 311 
than the ones from this study, of 66% and 65%, respectively, emphasizing the 312 
importance of highly- specialized management (10).   313 
All patients with M/XDR-TB in this study are not of Austrian origin. The ECDC TB 314 
report also suggests that over half of patients with TB in a lot of the countries of 315 
Western Europe are of foreign origin (10). This underscores the importance of 316 
migration in the epidemiology of MDR-TB. While in the countries of Western Europe 317 
most patients with MDR-TB have access to appropriate treatment, in other countries 318 
such as Russia less than half of the estimated 44,000 patients with MDR-TB were 319 
enrolled on treatment in 2011 (23), while in Ukraine, a country with a high-burden of 320 
MDR-TB due to conflict and population displacement many patients have difficulties 321 
in accessing treatment (24). More than half of the patients with M/XDR-TB in this 322 
study were from Chechnya. This might be because Austria has the second largest 323 
Chechen diaspora in Europe with a large proportion of refugees (25) and in 324 
Chechnya about a half of TB cases are MDR (26). 325 
Another factor that contributes to treatment accessibility and success is the cost of 326 
MDR-TB therapy. While a full course of MDR-TB treatment costs 70 times more than 327 
for pan-susceptible TB, costs for XDR-TB might be as 280-fold higher making it a 328 
considerable burden on countries where M/XDR-TB are prevalent (6).  329 
Interestingly, almost a tenth of the M. tuberculosis strains isolated were still 330 
susceptible to rifabutin. This underscores the importance of drug susceptibility 331 
testing for rifabutin, and if susceptible, including it in the therapy regimen which, due 332 
to its effectiveness, could potentially lead to a shorter duration of therapy and 333 
improved treatment outcomes. 334 
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A number of drugs of unclear efficacy against M. tuberculosis were used for the 335 
treatment of MDR-TB. Fusidic acid, an antibiotic which works via protein synthesis 336 
inhibition and active on gram-positive bacteria, was used as part of the drug regimen 337 
in almost a fifth of patients in the study. There was a trend showing a higher rate of 338 
favourable outcome in patients receiving fusidic acid, but the difference was not 339 
significant. In vitro studies have shown that fusidic acid has an inhibitory effect on M. 340 
tuberculosis growth (27, 28). As this drug has not been evaluated in early 341 
bactericidal activity studies or in clinical trials fusidic acid should be explored as a 342 
repurposed drug for the treatment of MDR-TB.  343 
Over two thirds of patients in this study were treated with linezolid, which has been 344 
shown to be effective in patients with M/XDR-TB (18, 29). A recently published meta-345 
analysis on linezolid-containing regimens reported favourable outcomes in 83% of 346 
patients treated with linezolid (30), however most of the studies were retrospective 347 
and had no control arm. Unfortunately, linezolid therapy is associated with frequent 348 
and sometimes severe adverse events requiring treatment discontinuation (30, 31). 349 
In the present study, linezolid therapy was also significantly associated with 350 
polyneuropathy in over 60% of patients.  351 
The multivariate analysis showed that a longer total duration of therapy, and the 352 
status of sputum culture at 6 months were associated with a favourable outcome. 353 
The M. tuberculosis strains from the patients included in the study had high rates of 354 
additional resistance to anti-tuberculosis drugs other than rifampicin and isoniazid.. 355 
Over 44% of strains had resistance to all first-line drugs, 49% had resistance to 356 
prothionamide, 46% had resistance to at least one second-line injectable drug and 357 
over a quarter had resistance to fluoroquinolones. These findings are in line with 358 
other recent observations on the level of bacillary drug resistance of MDR- M. 359 
17 
 
tuberculosis in the region (32, 33).This represents higher rates of resistance than 360 
that reported in studies using standardized treatment regimens for MDR-TB (34) and 361 
suggests that a standardized treatment approach should not be followed in the 362 
European Region as  patients may be treated with second line antituberculosis drugs 363 
that are not effective. Standardized treatment could lead to further acceleration of 364 
drug-resistance development. It is important to notice that with an individualize 365 
treatment approach high treatment success rates could be achieved despite the 366 
“MDR-TB plus” scenario in patients treated for M/XDR-TB in Vienna. 367 
MDR-TB requires a prolonged duration of therapy and is associated with an 368 
increased length of hospital stay, frequent and sometimes irreversible adverse 369 
events and extremely high costs. Due to the physical and psychological difficulties 370 
experienced by patients during the course of treatment, specialized support is of 371 
great value. It is very likely that the regular psychological counselling and social 372 
support given to the patients from this study, played an important contribution to 373 
improve treatment adherence and attain high rates of treatment success in this 374 
setting.  375 
Although this study is retrospective and lacks a direct comparison to other 376 
management strategies, it provides unique information on a large number of patients 377 
with pulmonary M/XDR-TB from a single-centre from a Western European country of 378 
a low tuberculosis-incidence.  379 
In conclusion this study shows that high rates of successful treatment outcome can 380 
be achieved in patients with M/XDR-TB in Europe when the drug regime is 381 
individualized to the results of 2nd line drug susceptibility testing and 2nd line drugs 382 
are available for the treatment without restrictions.  Additionally, the adequate 383 
funding to provide medications, appropriate testing and supportive care, treatment 384 
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adherence due to prolonged hospitalization and effective management of adverse 385 
events also played an important role in the high rates of treatment success.  The 386 
results also underscore the importance of a multidisciplinary treatment approach 387 
comprising individualized patient care, as well as psychological and social support to 388 
improve adherence to therapy and for the early detection and management of 389 
treatment-related adverse events (35). With these combined efforts, treatment 390 
outcomes for patients with M/XDR-TB can be substantially improved.  391 
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Tables and figures 565 
 566 
Figure 1. Spectrum of first- and second line anti-tuberculosis drug-resistance in 90 567 
strains of M. tuberculosis from patients with M/XDR-TB at Otto-Wagner Hospital, 568 
Vienna (Austria) admitted between 2003 and 2012.  569 
 570 
Figure 2. Drugs regimens for the treatment of M/XDR-TB.  571 
Regimens are represented according to their composition. In the central square it is 572 
shown how many patients received fluoroquinolones, aminoglycosides, both or none. 573 
Drugs are added along the lines. The number in the circle represents the number of 574 
the patients who go through that particular node. The black point (•) represents the 575 
number of patients ending the regimen in that node. AMC amoxicillin clavulanic acid; 576 
BDQ bedaquiline; CFZ clofazimine; CLA clarithromycin; CS cycloserine; DDS 577 
dapsone; EMB ethambutol; FQ fluoroquinolones; FUS fusidc acid; IMP imipenem; 578 
INJ second-line injectable drugs; LZD linezolid; PAS para aminosalicylic acid; PTO 579 
prothionamide; PZA pyrazinamide; RFB rifabutin; SXT trimethoprim- 580 
sulfamethoxazole. 581 
 582 
Figure 3. Smear (A) and culture (B) conversion during anti-tuberculosis treatment. 583 
Smear conversion is shown only for patients with a positive smear at treatment 584 
initiation. 585 
 586 
  587 
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Table 1. Characteristics of 90 patients with M/XDR-TB admitted between 2003 and 588 
2012 at the Otto-Wagner Hospital, Vienna (Austria)  589 
Variable MDR-TB 
N = 76 
XDR-TB 
N = 14 
p-value 
Male gender, n (%) 45/76 (59.2) 9/14 (64.3) 0.722 
Age (years), median (IQR) 30 (25.3-35.3) 33.5 (28.8-
42.3) 
0.101 
Country of birth, n (%) 
Former Soviet Union 
Other 
 
60/76 (78.9) 
16/76 (21.1) 
 
10/14 (71.4) 
4/14 (28.6) 
 
0.503 
Previous TB treatment, n (%) 38/69 (55.1) 10/13 (76.9) 0.142 
Cavitary disease, n (%) 50/76 (65.8) 12/14 (85.7) 0.211 
Smear positive at diagnosis, 
n (%) 
50/75 (66.7) 11/14 (78.6) 0.535 
Resistance to all first-line 
drugs, n (%) 
31/76 (40.8) 9/14 (64.3) 0.104 
Resistance to 
fluoroquinolones, n (%) 
9/75 (12) 14/14 (100) NA 
Resistance to second-line 
injectable drugs, n (%) 
28/76 (36.8) 14/14 (100) NA 
Number of drugs in the 
intensive phase, median 
(IQR) 
5 (5-6) 6 (6-6.3) 0.021 
29 
 
Number of drugs in the 
continuation phase, median 
(IQR) 
3 (3-4) 4 (3-4) 0.051 
Linezolid treatment, n (%) 49/76 (64.5) 12/14 (85.7) 0.177 
Bedaquiline treatment, n (%) 3/76 (3.9) 4/14 (28.6) 0.010 
Days in hospital, median 
(IQR) 
128 (89.8-
212.5) 
335 (190.5-
436.5) 
<0.001 
Duration of treatment 
(months), median (IQR) 
19.5 (17.8-24) 24 (22.3-24.8) 0.012 
Culture conversion, n (%) 71/65 (95.9) 14/14 (100) 1.00 
Time to smear conversion 
(days), median (IQR) 
56.5 (21-119.5) 128 (56-269.5) 0.024 
Time to culture conversion 
(days), n (%) 
61 (30.8-96) 110 (54.8-
288.8) 
0.010 
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Table 2. Treatment outcomes in patients with M/XDR-TB 592 
 MDR-TB 
N = 76 
XDR-TB 
N = 14 
Favourable outcome (cured + completed) 
Cured 
Completed  
56 (73.7) 
47 (61.8) 
9 (11.8) 
9 (64.3) 
9 (64.3) 
0 (0) 
Unfavourable outcome (died + failure) 
Died 
Failure 
2 (2.6) 
2 (2.6) 
0 (0) 
1 (7.1) 
1 (7.1) 
0 (0) 
Unknown outcome (default + transferred out) 
Default  
Transferred out 
16 (21) 
8 (10.5) 
8 (10.5) 
0(0) 
0 (0) 
0 (0) 
Still on treatment 2 (2.6) 4 (28.6) 
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